Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.
COVID-19
case report
common variable immunodeficiency disorders
convalescent plasma
immunodeficiencies
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
08
2020
accepted:
26
10
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as the optimal therapeutic strategy. We report a case of a 37-year old male with common variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After administration of convalescent plasma, the patient's condition improved rapidly. Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of symptoms. We propose that convalescent plasma might be considered as a treatment option in patients with CVID and severe COVID-19. In addition, in patients with immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.
Identifiants
pubmed: 33329586
doi: 10.3389/fimmu.2020.596761
pmc: PMC7714937
doi:
Substances chimiques
Antibodies, Viral
0
RNA, Viral
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
596761Informations de copyright
Copyright © 2020 Van Damme, Tavernier, Van Roy, De Leeuw, Declercq, Bosteels, Maes, De Bruyne, Bogaert, Bosteels, Hoste, Naesens, Maes, Grifoni, Weiskopf, Sette, Depuydt, Van Braeckel, Haerynck and Lambrecht.
Déclaration de conflit d'intérêts
AS is a consultant for Gritstone, Flow Pharma, Avalia. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569
pubmed: 32319118
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
Trials. 2020 Jun 22;21(1):554
pubmed: 32571428
Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600
pubmed: 32648959
J Med Genet. 2016 Sep;53(9):575-90
pubmed: 27250108
J Infect. 2020 Jul;81(1):e61-e66
pubmed: 32335173
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
Ann Allergy Asthma Immunol. 2020 Jul;125(1):112-114
pubmed: 32387167
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974